|
Hemato-oncology / Original Article
The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
Gi-June Min, Young-Woo Jeon, Sung-Soo Park, Silvia Park, Seung-Hawn Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Dong-Wook Kim, Jong-Wook Lee, Seok-Goo Cho
Korean J Intern Med. 2021;36(2):424-432. Published online February 24, 2020
Background/Aims: Idiopathic multicentric Castleman disease (iMCD) comprises approximately 30% of all cases of Castleman disease. It is characterized by constitutional symptoms, enlarged lymph nodes at multiple anatomical sites, and laboratory test abnormalities, which are primarily related to the o..
|
